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ABSTRACT: 
The 18kDa Translocator protein (TSPO) was discovered in 1977 and initially named 
“Peripheral-type benzodiazepine receptor” (PBR). It is located at the point of  contact between 
inner and outer mitochondrial membrane. It is associated with other membrane proteins to 
form the mitochondrial  permeability transition pore (MPTP). The expression of  TSPO is 
ubiquitary in peripheral tissues (steroid producing tissues, liver, heart, kidney, lung, 
immune system), and in the central nervous system is mainly located in glial cells and in 
neurons. It is involved in numerous functions including steroidogenesis, the transport and 
the synthesis of  heme, immunomodulation, the regulation of  apoptosis and generation of  
radical oxigen species (ROS). In the 1995 Dalpiaz et al. proposed a pharmacophore model 
later refined by Da Settimo et al. in 2008. On the basis of  these studies a series of  N,N-
dialkyl-2-phenylindol-3-ylglyoxylamide derivatives was synthesized and tested as TSPO 
ligands. The SARs of  these compounds were rationalized in light of  the 
pharmacophore/topological model of  TSPO binding site made up of  three lipophilic 
pockets (L1, L3 and L4) and a H-bond donor group (H1). The aim of  this work is the 
design and the synthesis of  a novel series of  N,N-dialkyl-2-phenylindol-3-ylglyoxylamide 
featuring suitable substituentes on the indole nucleus for good pharmacokinetic parameters. 
The affinity towards TSPO of  all the new compounds was tested by binding assays 
performed on rat kidney membranes. For those compounds which showed a Ki value in the 
sub-nanomolar range, the ability to induce functional effects trough the TSPO was also 
tested. In particular, since TSPO-related apoptosis and steroidogenesis are events which 
play key roles in the homeostasis of  cellular processes, we carried out experiments on cell 
growth in metabolic stress conditions. The status of  cellular stress was created by nutrient 
deprivation using low serum medium culturing conditions (1% fetal bovine serum FBS). 
The effects of  some compounds (the most promising ones in term of  affinity) were 
evaluated by proliferation MTS assay and crystal violet staining. The obtained results 
showed an increase in cell growth after 48 hours of  treatment with compounds, in respect 
to the control. If  such preliminary results are confirmed even in a cellular model of  primary 
neurons or in a neurodegenerative cell model, these compounds may be used as versatile 
scaffold for the design of  novel neuroprotective agents. 
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INTRODUCTION: 
The first benzodiazepine, chlordiazepoxide (Librium), was discovered accidentally 
in 1955 by Leo Sternbach, and made available in 1960 by Hoffmann-La Roche, 
who also marketed as diazepam (Valium) since 1963.[1] Starting in the sixties and 
seventies benzodiazepines have begun to be widely prescribed clinically. The 
extensive clinical use is based on their activities of powerful anxiolytics, 
anticonvulsants, sedative-hypnotics and muscle relaxants.[2] In humans exist two 
different forms of benzodiazepine receptors: central benzodiazepine receptors 
(CBRs) and peripheral benzodiazepine receptors (PBRs). 
The first type (CBRs) is found in the brain and forms an allosteric site on the 
GABAA receptor complex. In fact, ligands acting at this allosteric site, such as 
diazepam and chlordiazepoxide, enhance the affinity of the γ-aminobutyric acid 
(GABA) toward the CBR and, in this way, influence chloride (Cl-) influx at the 
GABAA receptor pore, causing downstream effects on GABA-mediated 
inhibition.[3] Different studies have shown benzodiazepines (BZs) acting on CBRs to 
be responsible for different GABAA-induced effects. 
The second type (PBRs) is first described in 1977 by Braestrup and Squires[4] as an 
alternative binding site in non-neuronal tissue for the diazepam, a centrally acting 
benzodiazepine. It was named peripheral according to this tissue distribution and 
benzodiazepine receptor because BZs is the class of ligands by which PBR was 
discovered. However, multiple other names have been used to refer to this protein, 
including mitochondrial benzodiazepine receptor (MBR), mitochondrial diazepam 
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binding inhibitor (DBI) receptor complex (mDRC), PK11195 binding sites (PKBs), 
isoquinoline binding protein (IBP), Omega3 receptor. [5]  
Recent data have increasingly supported the renaming of this protein with the aim 
to represent more accurately its sub-cellular role and putative tissue-specific 
functions. In 2006, a team of scientists has proposed the new name Translocator 
Protein (18 kDa), TSPO. [6]  In fact the name PBR was widely accepted mainly for 
historical reasons in the scientific community, but it didn’t take into account the 
new findings regarding its structure, subcellular roles and tissue distribution. It has 
also been shown that many ligands structurally different from BZs bind to this 
protein, which is not a receptor in the traditional sense, but rather a translocator of 
molecules. TSPO is an evolutionarily well-conserved and tryptophan rich 169-
amino acids protein with five trans-membrane domains which consist of extended 
α-helices composed of 21 residues, long enough to spam an entire membrane 
bilayer. These α-helices are linked by hydrophobic loops, with a carboxyterminal 
and a short amino-terminal tails located outside and inside the mitochondria, 
respectively. Furthermore, site-directed mutagenesis studies demonstrated that the 
portion of the receptor that recognized the ligands is located on the first 
cytoplasmatic loop TSPO forms complexes of four to six molecules whose 
organization is postulated to form a single pore, reflecting the function of TSPO as 
a transporter protein in the mitochondrial membrane. [5] The TSPO active shape 
appears the dimeric.[7] 
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However, the exact three-dimensional structure of TSPO has not yet been 
determined, as its close association to the membrane makes the purification and 
crystallization processes very difficult to accomplish. At a subcellular level, TSPO is 
mainly located on the mitochondrial outer membrane and particularly concentrated 
at outer/inner mitochondrial membrane contact sites. In addition, TSPO is also 
expressed at low levels in other subcellular compartments, such as plasma 
membranes and nuclear fraction of cells. In 1992 McEnery et al. reported that 
TSPO is strictly associated in a trimeric complex with VDAC, a voltage-dependent 
anion channel of 32 kDa located at sites of contact between outer and inner 
mitochondrial membrane that acting as a channel allowing passage of small 
molecules and ions into the mitochondria, and ANT, adenine nucleotide 
translocase, a specific antiporter of 30 kDa, located in the inner mitochondrial 
membrane, for the exchange of ATP and ADP as part of oxidative 
FIGURE (1): Three-dimensional structure of TSPO. (A) View perpendicular to the plane of the membrane of the TSPO 
dimer. (B) View parallel to the plane and after rotation of 40 °. (C) View perpendicular to the plane after 90 ° rotation. (D) 
Monomer TSPO view parallel to the plane from the side of the interface with the dimer. (E) TSPO monomer seen from the 
lipid bilayer. 
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phosphorylation. Together with other proteins, these three sub-units constitute the 
mitochondrial  permeability transition pore (MPTP).[8] 
 
FIGURE (2): Molecular structure of 18kDa TSPO and localization. It is also shown some proteins as-sociated with TSPO 
in the MPTP complex (VDAC, ANT and PRAX-1)[8] 
 
Furthermore, it has been identified four cytosolic TSPO-associated proteins which 
most of time play an important role in the biological processes where TSPO is 
involved. p10 is the first cytosolic protein associated to TSPO identified, but whose 
bio-chemical role has not been understood yet. It is a protein of 10 kDa that 
coimmunoprecipited with 18 kDa TSPO using the isoquinoline carboxamide 
radioactive probe PK14105, a ligand selective for mitochondrial benzodiazepine 
receptors, to photolabel rat mitochondrial preparations.[9] 
PBR associated protein-1 (PRAX-1) is isolated, cloning and characterized by 
Galiègue et al. in 1999.[10] It is a protein of 1857 amino acids with a molecular mass 
of 240 kDa, discovered using the yeast two-hybrid screening strategy. Exhibiting 
various domains involved in protein-protein interaction, such as proline-rich 
domains, leucine-zipper motifs and Src homology region 3-like (SH3-like) do-
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domains, it has been suggested that PRAX-1 acts as an adaptor protein to recruit 
additional targets to the vicinity of TSPO so as to modulate its function. In 
addition, it was assumed that a single PRAX-1 protein interacts with the C-terminal 
end (14 amino acids) of several molecules of TSPO (at least two of them). 
 
FIGURE (3): Chromosomal localization of the human PRAX-1 gene. A, FISH mapping of the human PRAX gene. The 
left panel shows the FISH signals on chromosome. The arrow indicates the specific site of hybridization to chromosome 17. 
The right panel shows the same mitotic figure stained with DAPI to identify chromosome 17. B, idiogram of the human 
chromosome 17 illustrating the distribution of labeled sites for the human PRAX-1 probe. Each dot represents the double 
FISH signals detected on human chromosome17. 
 
Another important protein functional associated to TSPO is Steroidogenic Acute 
Regulatory Protein (StAR), that mediates the flow of cholesterol from the outer to 
the inner mitochondrial membrane, permitting steroid formation in steroidogenic 
cells. Further studies indicated that StAR acts at the outer mitochondrial membrane 
and it is not needed to allow the entry of cholesterol into mitochondria. Therefore, 
Hauet et al. suggest that TSPO and StAR work in concert to bring cholesterol into 
mitochondria and in particular TSPO serves as a gatekeeper in cholesterol import 
into mitochondria and StAR plays the role of the hormone-induced activator.[11, 12] 
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PKA-associated protein 7 (PAP7) is a cytosolic protein with a molecular mass of 52 
kDa involved in the hormonal regulation of steroid formation, interacting with both 
the cytosolic RIα subunit of PKA and TSPO. Particularly, PAP7 targets the PKA 
isoenzyme, linked to increased steroid synthesis, which phosphorylating specific 
protein substrates induces the reorganization of TSPO topography and function.[13] 
 
 
 
 
 
 
 
FIGURE (4): Biological Assembly Image for 3P0L. Human steroidogenic acute regulatory protein. 
FIGURE (5): mRNA Expression of PAP7 in Mouse Tissues Examined by in Situ Hybridization with an antisense 35S-
labeled cRNA probe to full-length PAP7. Brain sagittal section. 
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ROLE OF TSPO IN CELLULAR 
FUNCTION: 
 
 REGULATION OF STEROIDOGENESIS. 
The location of TSPO on the outer mitochondrial membrane and the extremely 
high density in steroidogenic endocrine tissues, such as adrenocortical cells and 
Leydig cells, suggest that TSPO plays an important role in steroidogenesis. 
Moreover, different publications report that this protein ligands stimulate steroid 
biosynthesis in adrenal, placental, testicular, ovarian and glial systems.[14, 15] 
The biosynthesis of steroids begins with the enzymatic transformation of cholesterol 
into pregnenolone, which occurs through cholesterol side-chain cleavage by the 
cytochrome P450scc (CYP11A1) and auxiliary electron transferring proteins, 
localized on the matrix side of the inner mitochondrial membrane. Pregnenolone 
then leaves mitochondria to move to the endoplasmic reticulum, where it is 
transformed in the final steroid products. [6, 7, 11] 
The rate-limiting step is the translocation of cholesterol from the cellular stores 
across the aqueous intermembrane space to the inner mitochondrial membrane and 
P-450scc. The fundamental role of TSPO in this mitochondrial cholesterol transport 
and thus in steroids synthesis is supported by numerous data, and particularly 
knockout and antisense experiments in vitro have demonstrated that down-
regulation of TSPO causes a decrease in steroid synthesis.[7, 14, 15] 
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FIGURE (6): Transport of cholestrerol, across the mitochondrial membrane, from the intracellular space within the 
mitochondria, by the TSPO. 
 
The topographic study of TSPO in the mitochondrial membranes have also shown 
that after treatment of Leydig cells with a steroidogenesis stimulator, such as 
choriogonadotrophin hormone (hCG), there are various morphological changes, 
such as a formation of large complexes of 15-25 molecules of TSPO and a rapid 
reorganization of their localization in the mitochondrial membrane, as well as a 
rapid increase in TSPO ligand binding.[7, 14]  
Moreover, amino acids deletion, site-directed mutagenesis and structural studies 
have permitted to identified a cholesterol recognition amino acid consensus (CRAC) 
sequence in the cytosolic carboxy-terminal domain of the TSPO that could be part 
of the binding site for the uptake and translocation of cholesterol (channel-like 
interaction) through a channel delimited by five α-helixes of  TSPO. However, for 
cholesterol delivery into mitochondria TSPO-mediated is also required the 
interaction of TSPO with StAR, a protein acting as hormone-induced activator.[6, 7, 
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14] It has been observed a relationship between steroid levels, TSPO levels and 
anxiety, principally due to the fact that neurosteroids are endogenous modulators of 
the GABAA receptor. In general TSPO levels, determined by radioligand binding to 
platelets, decrease in patients with anxiety disorders. Therefore, ligands binding to 
TSPO located in glial cells, such as N,N-dialchyl-2- pheniylindol-3-ylglyoxylamides 
synthesized by Da Settimo et al.,[16] provide the cholesterol necessary to restore 
neurosteroid synthesis and increase pregnenolone formation, which is then 
metabolize to form allopregnanolone, a potent allosteric modulator of the GABAA 
exerting anxiolytic effects. In this sense TSPO could be considering a promising 
target for the psychiatric disorders that involve dysfunction in steroid 
biosynthesis.[11, 17] 
It also has been observed that the systemic levels of steroids increase as a result of a 
lesion, to a pain or a fever, in response to stimulation by certain cytokines secretion 
of corticotropin releasing factor. The involvement of TSPO in the synthesis of 
steroids can contribute to this defense mechanism.[20] 
 
 REGULATION OF APOPTOSIS 
MPTP plays an important role in the modulation of signaling pathways mediating 
apoptotic and necrotic cell death. The exact composition of the MPTP is not yet 
established, but it has been recognized various proteins implicated in pore 
formation and its regulation: an hexokinase, in the cytosol; a trimeric complex 
constituted by VDAC, ANC and TSPO; a creatine kinase in the intermembrane 
space and cyclophilin D in the matrix. MPTP allows the transfer of solutes, 
including ATP/ADP exchange, from the mitochondrial matrix to cytosol, through 
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the VDAC/ANC conduit, and there-fore facilitates the crossing of the highly 
impermeable mitochondrial inner membrane. This periodic transient increase in 
permeability by the MPTP allows the pumping of protons from the inner 
membrane by the electron transport chain and creates the transmembrane 
electrochemical gradient that derives ATP synthesis.[7, 18] 
Several factors cause the opening of the MPTP: high [Ca2+] is the fundamental 
trigger but alone is not enough, also low adenine nucleotide concentrations, high 
phosphate concentrations, oxidative stress and pro-apoptotic proteins. Pore opening 
leads to the dissipation of transmembrane electrochemical gradient, uncoupling of 
mitochondria and swelling, resulting in the release of cytochrome c and apoptosis 
inducing factor (AIF) into the cytosol. Once in the cytosol, the first induces the 
caspase cascade ending in the destruction of cell nucleus, cytoskeleton and plasma 
membrane; the second principally leads to nuclear chromatin condensation, DNA 
fragmentation and then to cell death.[18] 
 
 
FIGURE (7): Intracellular events which follow the MPTP opening and  lead to apoptosis. 
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The exact events which TSPO modulates apoptosis are still unknown. In 2008 
Veenman et al.[34] suggested that interaction between VDAC and TSPO is 
fundamental to initiate the mitochondrial apoptosis pathway. The intermediary 
agent between TSPO and VDAC was supposed to be provided by mitochondrial 
ROS (reactive oxygen species) generation under the control of the same TSPO. 
ROS lead first to dissociation of cytochrome c from oxidized cardiolipins located at 
the inner mitochondrial membrane and, subsequently to its release in the cytosol 
via formation of a pore due to assemblage of VDAC molecules. In 2007 Azarashvili 
et al.[19] supposed  another possible mechanism that provided evidence for TSPO 
involvement in MPTP opening, controlling the Ca2+-induced Ca2+ efflux and AIF 
release from mitochondria, important stage of initiation of programmed cell death. 
It has also been observed a modulation by TSPO of interactions between VDAC or 
ANT and pro-apoptotic or anti-apoptotic proteins (Bcl-2 and Bax). Therefore, it has 
been designed TSPO ligands with pro-apoptotic effects acting as anticancer 
agents.[20] 
 
 IMMUNOMODULATION 
The presence of the TSPO in a large number of cells immunomodulatory such as 
the microglia, the blood monocytes, lymphocytes, and leucocit, led to think of an 
involvement of TSPO in the immune response. It has been shown, in special studies 
in mice, that some TSPO ligands, specifically benzodiazepines, have an 
immunosuppressive action, inhibiting the capacity of macrophages to produce ROS 
and inflammatory cytokines such as IL-1 (interleukin-1), TNFα (tumor necrosis 
factor alpha) and IL-6, and regulating phagocyte oxidative metabolism required for 
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elimination of foreign antigens. Moreover, the TSPO is involved in oxidative 
metabolism by phagocytes, a process necessary to permanently delete the foreign 
antigens. The  immunosuppressive action of certain  ligands for the TSPO shown 
the important role played by this protein in the inflammatory response. [7] 
 
 TSPO AND NEUROINFLAMMATION 
The neuroinflammation are characteristic of many pathological conditions 
including neurodegenerative diseases such as Alzheimer, Parkinson's disease, 
metabolic and hepatic encephalopathy and repair processes following damage to 
cerebral and peripheral level.[21] 
Specific ligands with nanomolar affinity for the TSPO, such as PK 11195 and Ro5-
4864, were used to determine the parameters of the interaction ligand-receptor in 
brain tissue. The TSPO has been identified in the ependymal cells in the olfactory 
bulb and the choroid plexus later in glial cells, including microglia and astrocytes. 
Using the radioligand [3H]-PK 11195 in animal models has been found an increase 
of the concentration of TSPO in numerous neurological diseases including multiple 
sclerosis, brain trauma, encephalitis and stroke. In most of these studies it was 
found an up-regulation of TSPO where the microglia is activated. Thanks to recent 
studies is possible obtain images of activated microglia through the use of PET( 
positron emission tomography) with ligands for the TSPO labeled with 11C or 18F. 
 
 OTHER FUNCTIONS 
Numerous studies on the functions of TSPO shown the modulation of its 
expression in physiological and pathological states, including the cellular response 
18 
 
in viral infections. One of the strategies adopted by viruses to bypass the protective 
mechanisms of cells against infection is to block apoptosis. Several pathogenic 
viruses using just the TSPO as a target to implement this block. This discovery 
therefore offers numerous prospects for new antiviral strategies.[20] 
Other functions included protein import, important for membrane biogenesis and 
confirmed by the observation that TSPO is necessary for the import of StAR protein 
into mitochondria; TSPO, binding of dicarboxylic porphyrin and transport into 
mitochondria, have been reported as well as a relationship between TSPO and 
heme biosynthesis pathway; ion transport and calcium homeostasis, since it has 
been shown that TSPO regulates the Ca2+ flow into the cell. Furthermore, TSPO 
plays an important role in cellular respiration and mitochondrial oxidation, and 
affects cellular proliferation and differentiation in a number of cell types.[6] 
The activity of TSPO is also implicated in stress. Its activation during acute 
exposure to stressors can be seen as a predisposition to metabolic and neuronal 
better adaptation to stress.[20] 
High expression of this receptor has also been observed in neoplastic cells and 
tissues of the ovary, and adenocarcinom in the liver and colon cancer. This increase 
is correlated with the degree aggressiveness of tumor. The monitoring of the 
expression of this receptor, therefore, may be relevant in a clinical procedure for 
diagnosing and/or to follow the progression of the disease. 
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TSPO LIGANDS: 
 
 TSPO ENDOGENOUS LIGANDS 
A wide variety of endogenous molecules with affinity for the TSPO and different 
chemical structures have been identified. One of the first molecules identified, 
isolated both at central and pheripheral tissues (adrenal gland, kidney and testes), is 
a residue of neuropeptides (11 kDa) composed of 86 aa, which inhibits the binding 
of diazepam with the receptor site of the BZs called "inhibitor of the binding of 
diazepam (DBI)". In addition to this molecule and its metabolites have been 
isolated other endogenous ligands: Protoporphyrins (protoporphyrins IX, 
mesoporphyrins IX, deuteroporphyrins IX, hemin) exhibit a very high affinity for 
TSPO. As several steroidogenic tissues, such as the adrenal gland and testis, show 
high TSPO and porphyrin levels, it has been suggested a physiological role for the 
interaction of these two molecules. Furthermore, having a plane of symmetry, these 
molecules could bind dimerized form of TSPO, confirming in this way the 
postulated two-binding site model.[7, 15] 
 
FIGURE (8): Chemical structures of protoporphyrin IX (1) and heme (2). 
 
20 
 
Another endogenous ligand is cholesterol, as previously reported discussing the 
fundamental role of TSPO in the regulation of cholesterol transport and thus in the 
steroidogenesis. Again it has been shown that a dimeric form of TSPO possesses an 
enhanced binding capacity to cholesterol. [15] 
Finally, anthralin, isolated in the stomach of rat, a 16 kDa protein that has been 
demonstrated interact with both TSPO and dihydropyridine binding site, and 
phospholipase A2 have also been proposed as endogenous ligands for TSPO.
 [15] 
 
 TSPO SYNTHETIC LIGANDS 
Synthetic TSPO selective ligands have been developed with the aim to deepen the 
knowledge of the exact pharmacological role of TSPO, to define its involvement in 
several patho-physiological conditions and to establish the structural requirements 
needed for an optimum of affinity. Initially, the most of these ligands have been 
designed starting from classical selective CBR ligands, such as benzodiazepines, 
making the necessary structural modifies in order to shift the affinity toward TSPO. 
Until to date, the prototypic ligands, used as reference compounds in the 
development of TSPO pharmacophore models and in SAR studies, are the 
benzodiazepine Ro 5-4864 (3) and the isoquinolinecarboxamide PK11195 (1), 
classified by LeFur and coworkers the first as a TSPO agonist or partial agonist and 
the second as an antagonist.[7] 
The ligands for the TSPO not have a fixed chemical structure, but are very different 
among them. We can distinguish nine classes of compounds:  
 In the class of benzodiazepines the selectivity toward the TSPO or CBR 
results very sensitive even to slight structural modifications: in fact, in the 
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case of Ro 5-4864 (3) the insertion of a chlorine at the para position of the 
pendant phenyl rings of the diazepam, equipotent at the two receptors, shifts 
the selectivity toward TSPO. Ro 5-4864 has been used in a number of 
studies aimed at characterizing TSPO, and particularly by Gavioli and 
colleagues to study the putative role of TSPO as a target for the treatment of 
psychiatric disorders.[5] 
 Benzothiazepines, a class of TSPO ligands featuring a 6,7 bicyclic nucleus, 
were initially developed by Campiani and coworkers as selective ligands for 
CBR and GABA receptor subtypes. Some pyrrolobenzothiazepines 
derivatives possess an unexpected significant inhibitory activity at L-type 
calcium channels, equal to or higher than those of reference calcium 
antagonists such as verapamil and (+)-cis-diltiazem. [5] 
 On the basis of pyrrolobenzothiazepine skeleton, the pyrrolobenzoxazepine 
scaffold has been developed, featuring the replacement of the endocyclic 
sulfur (S5) with an oxygen (O5), that increases affinity by 2-3 fold. Some of 
these compounds showed an high affinity toward the TSPO (Ki values in the 
low nanomolar-subnanomolar range) and the capacity to stimulate 
steroidogenesis in mouse Y-1 adrenocortical cell line. [5] 
 Isoquinolinecarboxamide PK 11195 (1) is the first non-benzothiazepine ligand 
binding the TSPO with nanomolar affinity and it is widely used for studies 
aimed to define and map the binding site. In 2008 Chelli et al.[22] showed 
that treatment of a human astrocytoma cell line (ADF) with PK 11195 
actives an autophagic pathway followed by apoptosis mediated by 
mitochondrial potential dissipation. Moreover, has been showed that PK 
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11195 has a multidrug resistance modulating activity increasing the efficacy 
of a daunorubicin treatment on human multidrug-resistant leukemia cell line 
in vitro by 5-7 fold and blocking p-glycoprotein efflux, a transporter whose 
activity contributes to limit antitumor drug efficacy.[20] 
 Alpidem (4) can be considered the progenitor of the class of imidazopyridines 
known to bind both TSPO and CBR with the nanomolar affinity (Ki 0.5-7 
nM and 1-28 nM, respectively). [5] 
 Phenoxyphenylacetamide derivatives, such as DAA1097 (9), were designed by 
a process of molecular simplification involving the opening of the diazepine 
ring of Ro 5-4864. Some compounds of this class of TSPO ligands have also 
showed potent anxiolytic properties in laboratory animals. [5] 
 Pyrazolopyrimidineacetamides, i.e. DPA714 (10), were first described by 
Selleri and coworkers as bioisosters of the imidazopyridines and thereby 
closely related to alpidem. 
 Indoleacetamide derivatives, collectively named FGIN-1 (9), was developed 
by Kozikowski and colleagues as a new class of compounds binding with 
high affinity and selectivity for TSPO. [5] 
      In a recent study SSR180575 (11), an indoleacetamide compound, was 
shown to have       neuroprotective properties in different models of 
progressive degeneration of the PNS and CNS: precisely it promotes 
neuronal survival and repair following axotomy through the regulation of 
apoptosis of glial cells and/or the production of mediators such as 
neurosteroids, cytokines or other neurotrophic factors that support nerve 
survival.[20] 
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 Indol-3-ylglyoxylamides. 
 
 
         
 
 
DAA 1097 (9) DPA 714 (10) SSR 180575 (11) 
 
FIGURE (9): Structures of some known TSPO ligands 
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INTRODUCTION TO EXPERIMENTAL 
SECTION: 
 
 N,N-DIALKYL-2-PHENYLINDOL-3-
YLLYOXYLAMIDES 
TSPO expression is up-regulated in several human pathologies, including gliomas 
and neurodegenerative disorders (Huntington’s and Alzheimer’s diseases) as well as 
in various forms of brain injury and inflammation. Under neuroinflammatory 
conditions, TSPO markedly increases in activated microglia.[26] Changes in TSPO 
level have been found in patients affected by generalized anxiety, panic, post-
traumatic stress, obsessive-compulsive disorders, and separation anxiety. 
Consequently, TSPO has been suggested as a promising target for a number of 
therapeutic applications[20] and also as a diagnostic marker for related disease 
progression. Therefore, many groups have been searching for TSPO ligands with 
improved performance for quantifying TSPO expression. 
Subsequently, a number of diversified structures have been developed obtaining in 
some cases good results in term of affinity and selectivity, and leading to drawing 
various TSPO pharmacophore models useful to design novel synthetic derivatives. 
Neverthless, the  topology of the TSPO binding cleft has not yet been completely 
defined. In 2004 Primofiore et al.[24] prepared and tested a series of N,N-dialkyl-2-
phenylindol-3-ylglyoxylamide derivatives I (TABLE 1) as TSPO ligands, designed 
as conformationally constrained analogues of the indoleacetamides of the FGIN-1 
(5) series previously described by Kozikowski and coworkers. Most of these 
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compounds showed a high affinity for TSPO in the nanomolar / subnanomolar 
range and a high selectivity for TSPO over CBR. The TSPO/CBR selectivity was 
evaluated by binding studies using membranes from rat brain tissues and 
[3H]flumazenil as radioligand. For some of these TSPO ligands with high affinity, 
the ability to stimulate pregnenolone formation from rat C6 gliomas cells was 
evaluated.  
 
TABLE 1: TSPO binding affinity of N,N-dialkylindolylglyoxylamide derivatives Ia-Iaah. [a]The concentration of tested 
compounds that inhibited [ 3H-PK 11195 ] binding to rat kidney mitochondrial membranes ( IC50 ) by 50% was determinate 
with six concentrations of the displacers, each performed in  triplicate. Ki values are the mean ± SEM of the three 
determinations. [b] the inhibition percent of [ 3H ]-flumazenil specific binding at 10µM of the compound are the mean ± 
SEM of five determination Ki values are the mean ± SEM of three determinations. [ c ] Data taken from ref. 23. 
 
                                               
N 
 
R1 R2 R3 R4 R5 R6 Ki (nM) or inhibition 
(%)[c] 
 TSPO [a] CBR [b] 
Ro 5-
4864 
 
      23.o±3.0  
PK 
11195 
 
      9.30±0.5  
Alpidem       0.5 – 7 1 -28 
Ia (CH2)2CH3  
 
H H  H H  H  815±80 3293±381 
Ib (CH2)3CH3 H H H H H 1167±99 12% 
Ic CH2CH3 CH2CH3 H H H H 43.0±4  
Id (CH2)2CH3 (CH2)2CH3 H H H H 12.2±1.0 16% 
Ie (CH2)3CH3 (CH2)3CH3 H H H H 7.5±0.7 3% 
If (CH2)4CH3 (CH2)4CH3 H H H H 16.0±2.0 3% 
Ig (CH2)5CH3 (CH2)5CH3 H H H H 1.4±0.2 10% 
Ih CH2(CH3)2 CH2(CH3)2 H H H H 103±9.0  
Ii CH(CH3)CH2CH3 CH(CH3)CH2CH3 H H H H 17.0±2.0 5% 
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Ij CH2CH3 CH2C6H5 H H H H 11.0±1.0  
Ik                  -(CH2)4- H H H H 2400±125 4% 
Il                  -(CH2)5- H H H H 665±30 3% 
Im                  -(CH2)6- H H H H 33.0±3.0 3% 
In (CH2)2CH3 (CH2)2CH3 F H H H 4.28±0.32 4.3% 
Io (CH2)3CH3 (CH2)3CH3 F H H H 2.40±0.81 0% 
Ip (CH2)5CH3 (CH2)5CH3 F H H H 0.37±0.13 0% 
Iq CH2CH3 CH2C6H5 F H H H 1.68±0.12 10% 
Ir (CH2)2CH3 (CH2)2CH3 Cl H H H 4.65±0.52 14% 
Is (CH2)3CH3 (CH2)3CH3 Cl H H H 1.00±0.27 0% 
It (CH2)5CH3 (CH2)5CH3 Cl H H H 0.55±0.19 4.2% 
Iu CH2CH3 CH2C6H5 Cl H H H 1.30±0.15 7.3% 
Iv (CH2)2CH3 (CH2)2CH3 NO2 H H H 0.95±0.1  
Iw (CH2)3CH3 (CH2)3CH3 NO2 H H H 0.23±0.07  
Ix (CH2)5CH3 (CH2)5CH3 NO2 H H H 0.27±0.10  
Iy CH2CH3 CH2C6H5 NO2 H H H 0.55±0.02  
Iz (CH2)2CH3 (CH2)2CH3 CF3 H H H 1.69±0.2  
Iaa (CH2)3CH3 (CH2)3CH3 CF3 H H H 1.16±0.1  
Ibb (CH2)5CH3 (CH2)5CH3 CF3 H H H 1.0±0.1  
Icc CH2CH3 CH2C6H5 CF3 H H H 1.0±0.1  
Idd (CH2)2CH3 (CH2)2CH3 CH3 H H H 5.50±0.98  
Iee (CH2)3CH3 (CH2)3CH3 CH3 H H H 3.80±0.91  
Iff (CH2)5CH3 (CH2)5CH3 CH3 H H H 1.60±0.13  
Igg CH2CH3 CH2C6H5 CH3 H H H 2.64±0.1  
Ihh (CH2)2CH3 (CH2)2CH3 H H H F 2.67±0.48  
Iii (CH2)3CH3 (CH2)3CH3 H H H F 4.00±0.15  
Ijj (CH2)5CH3 (CH2)5CH3 H H H F 0.37±0.12  
Ikk CH2CH3 CH2C6H5 H H H F 1.33±0.2  
Ill (CH2)2CH3 (CH2)2CH3 H H H Cl 2.80±0.3 10% 
Imm (CH2)3CH3 (CH2)3CH3 H H H Cl 4.91±0.4 13% 
Inn (CH2)5CH3 (CH2)5CH3 H H H Cl 58.4±6 3% 
Ioo CH2CH3 CH2C6H5 H H H Cl 4.6±0.5  
Ipp (CH2)2CH3 (CH2)2CH3 H H H NO2 20.2±2.02 0% 
Iqq (CH2)3CH3 (CH2)3CH3 H H H NO2 21.6±2.15 1% 
Irr (CH2)5CH3 (CH2)5CH3 H H H NO2 30.3±9.15 0% 
Iss CH2CH3 CH2C6H5 H H H NO2 18.3±0.15 0% 
Itt (CH2)2CH3 (CH2)2CH3 H H H OCH3 328±45 8.6% 
Iuu (CH2)3CH3 (CH2)3CH3 H H H OCH3 65.2±3.4 8.8% 
Ivv (CH2)5CH3 (CH2)5CH3 H H H OCH3 35.5±8.7 7.3% 
Iww CH2CH3 CH2C6H5 H H H OCH3 69.5±3.6 5.7% 
Ixx (CH2)2CH3 (CH2)2CH3 F H H Cl 2.83±0.08 14% 
Iyy (CH2)3CH3 (CH2)3CH3 F H H Cl 3.05±0.45 17% 
Izz (CH2)5CH3 (CH2)5CH3 F H H Cl 7.75±1.55  
Iaaa CH2CH3 CH2C6H5 F H H Cl 4.01±0.26 9.7% 
Ibbb (CH2)2CH3 (CH2)2CH3 F H H F 6.73±1.39  
Iccc (CH2)3CH3 (CH2)3CH3 F H H F 4.36±0.05  
Iddd (CH2)5CH3 (CH2)5CH3 F H H F 0.95±0.1  
Ieee CH2CH3 CH2C6H5 F H H F 1.67±0.37  
Ifff (CH2)2CH3 (CH2)2CH3 Cl H H Cl 0.62±0.06 5% 
Iggg (CH2)3CH3 (CH2)3CH3 Cl H H Cl 1.9±0.2 0% 
Ihhh (CH2)5CH3 (CH2)5CH3 Cl H H Cl 5.8±0.6 3% 
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Iiii CH2CH3 CH2C6H5 Cl H H Cl 3.33±0.3  
Ijjj (CH2)2CH3 (CH2)2CH3 H H Cl H 14.0±1.5 0% 
Ikkk (CH2)3CH3 (CH2)3CH3 H H Cl H 3.40±0.3  
Illl (CH2)5CH3 (CH2)5CH3 H H Cl H 2.4±0.3 0% 
Immm CH2CH3 CH2C6H5 H H Cl H 5.0±0.4 0% 
Innn (CH2)2CH3 (CH2)2CH3 H H CH3 H 25.0±3.0  
Iooo (CH2)3CH3 (CH2)3CH3 H H CH3 H 6.0±0.6  
Ippp (CH2)5CH3 (CH2)5CH3 H H CH3 H 1.90±0.1  
Iqqq CH2CH3 CH2C6H5 H H CH3 H 2.30±0.2  
Irrr CH3 CH2CH3 H H H H 940±120 15% 
Isss CH3 (CH2)3CH3 H H H H 53.3±4.0  
Ittt CH3 (CH2)4CH3 H H H H 12.1±1.0  
Iuuu CH2CH3 (CH2)3CH3 H H H H 12.6±1.0  
Ivvv CH3 CH2CH3 Cl H H Cl 9.54±1.29 15% 
Iwww CH3 (CH2)3CH3 Cl H H Cl 0.15±0.02  
Ixxx CH3 (CH2)4CH3 Cl H H Cl 0.18±0.02  
Iyyy CH2CH3 (CH2)3CH3 Cl H H Cl 0.36±0.04  
Izzz CH3 CH2C6H5 H H H H 12.0±1.0  
Iaab CH3 CH2C6H5 F H H H 1.8±0.1  
Iaac CH3 (CH2)3CH3 Cl H H H 11±1.0  
Iaad CH3 (CH2)4CH3 Cl H H H 3.4±0.4  
Iaae CH2CH3 (CH2)3CH3 Cl H H H 3.6±0.4  
Iaaf CH3 (CH2)3CH3 H H H Cl 3.9±0.5  
Iaag CH3 (CH2)4CH3 H H H Cl 3.6±0.5  
Iaah CH2CH3 (CH2)3CH3 H H H Cl 1.8±0.2  
 
 
In 2008 the same research group[16] refined the TSPO pharmacophore/topological 
model through the synthesis and the biological evaluation of novel indole 
derivatives with the general formula I, bearing different combinations of 
substituents R1-R6.  (TABLE 1) 
 
FIGURE (10): TSPO pharmacophore/topological model. 
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Within this class, SAR findings were rationalized in the light of a 
pharmacophore/receptor model made up of three lipophilic pockets (L1, L3, and 
L4) and an H-bond donor group. Specifically, the second carbonyl group of the 
oxalyl bridge engages an H-bond with the donor site H1; the two lipophilic 
substituents on the amide nitrogen, R1, and R2 (linear or ramified alkyl, arylalkyl 
groups) interact hydrophobically with the L3 or L4 lipophilic pockets; the 2-phenyl 
moiety establishes a putative π-stacking interaction within the L1 pocket. The high 
affinities of these 2-phenylindolglyoxylamide derivatives have recently permitted 
the development of new fluorescent probes useful for investigating the localization 
and the expression level of TSPO.[32, 26] 
In TABLE 1 the binding affinity of compounds Ia-Iaah [16, 24 ] and of the standard 
TSPO ligands Ro5-4864 (2), PK 11195 (5) and Alpidem (6), expressed as Ki values 
has been reported. It has been observed that, among the unsubstitued derivatives Ia-
Im (R3 = R4 = R5 = R6 = H), N-monosubstitued compounds Ia-Ib show the lowest 
affinity probably because they cannot occupy both the L3 and L4 lipophilic pockets. 
The N,N-disubstitued indolylglyoxylamides instead exhibit a high affinity and in 
particular compound Ig, bearing two n-hexyl groups, is the most potent, with a Ki of 
1,4 nM. Therefore, increasing the length of the linear N-alkyl groups has been 
observed an enhancement of affinity, due to the better filling of L3 and L4 lipophilic 
pockets.[24] Subsequently, the three derivatives Id, Ie, Ig and Ij has been selected as 
leads for further affinity optimization efforts. It has been observed that the insertion 
of an electron-donating lipophilic group, such as a methyl group (Idd-Igg), in the 4’-
position (R3) of the 2-phenyl ring does not produce any gain in affinity respect to 
the parent unsubstitued compound. Introducing an electron-withdrawing 
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substituent such as Cl, F, NO2 and CF3 (In-Icc), it has been instead obtained 
compounds with higher affinity, and among these ones, the N,N-di-n-hexyl 
derivatives Ip (Cl), It (F), Ix (NO2) and Ibb (CF3) have been revealed the most 
potent, with Ki values of 0.37 nM, 0.55 nM, 0.27 nM and 1 nM, respectively. These 
results suggest that the R3 substituent has to be electron-withdrawing to reinforce 
the putative π-stacking interaction with an electronrich aromatic ring within the L1 
pocket. The data of affinity of compounds Ihh-Iww bearing a substituent in the 5-
position of the indole nucleus (F, Cl, NO2, OCH3) suggest that R6 has to be 
electron-withdrawing and also very small for optimal binding, and only Ijj with a 
fluorine at the 5-position features these properties (Ki = 0.37 nM). The introduction 
of two halogens in both 4’- and 5-positions (Ixx-Iiii; Ivvv-Iyyy) does not increase 
affinity in additive manner, but it has supposed a correlation with the nature of the 
N,N-dialkyl chain. Substitutions at the 7-position of the indole nucleus (R5) with an 
electron-withdrawing (Cl, Ijjj-Immm) or an electron-donating (CH3, Innn-Iqqq) 
lipophilic group do not produce any gain in affinity.  
The binding data of asymmetrical N,N-dialkyl derivatives (Irrr-Iaah), designed to 
probe the L3 and L4 lipophilic pockets at the TSPO binding site, indicate that the L3 
and L4 pockets are probably different in their dimensions, and that R1 and R2 have 
to be of different size to obtain the best-performing substitution on the amide 
nitrogen. Therefore, an aromatic moiety on R1/R2 substituents is equivalent to an 
aliphatic moiety of similar size in interacting with the two lipophilic pockets. 
In the light of all these findings, research is currently focused towards the synthesis 
and biological evaluation of a series of N,N-dialkyl-2-phenylindol-3-ylglyoxylamides (II) 
bearing a polar group at the 4’-position of the 2-phenyl ring (R3 = NH2, OH, 
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COOH), and of a series of N,N-dialkyl-2-(3-thienyl)indol-3-ylglyoxylamides (III). 
These compounds have been synthesized as symmetrical amides featuring linear 
alkyl chains of different length on the amide nitrogen (n-propyl, n-butyl, n-hexyl) to 
evaluate any changes in the interaction with the lipophilic pockets L3, L4 of the 
pharmacophore. The TSPO affinity of intermediary compounds featuring a OCH3 
and a COOCH3 substituent in 4’-position has also been estimated. 
 
FIGURE(11): Chemical structures of N,N-dialkyl-2-phenylindol-3-ylglyoxylamides (II) and N,N-dialkyl-2-(3-thienyl)indol-
3-ylglyoxylamides (III). 
 
To make these molecules are used as potential drugs or radiopharmaceuticals (as 
biomarkers of neuroinflammation), they must have a good pharmacokinetic profile. 
Therefore, the choice to insert a polar group in the scaffold of indolylglyoxylamide 
derivatives has the purpose to improve the lipophilic/hydrophilic balance, thus 
avoiding a high level of non-specific binding, a poor signal-to-noise ratios, a high 
plasma protein binding and thus a relatively poor penetration of the blood-brain 
barrier, resulting in accumulation of tracer in the brain. 
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EXPERIMENTAL SECTION: 
In this thesis work compounds 29, 30, 31 (2-(3-thienyl)), 31, 32 (R3 = NH2), 35, 36 
(R3 = OH), 37, 38, 39 (R3 = COOH). It has also been estimated the Ki value of 20, 
21, 22 (R3 = OMe), 23, 24 , 25, (R3 = COOMe) were prepared and biologically 
evaluted. 
The general synthetic procedures employed to prepare these compounds are shown 
in Scheme 1 and 2. They involve, as first step, the synthesis of the 2-phenylindoles 
16a-c and 2-(3-thienyl) indole 27 through a one-step Fischer indole synthesis[16] 
consisting in warming phenylhydrazine hydrochloride and the appropriate ketone 
acetophenone, methyl 4-acetylbenzoate, acetylthiophene directly with an excess of 
acid catalyst PPA (polyphosphoric acid). The reaction mixture was then poured 
into ice and the solid precipitated was collected by filtration and purified by 
recrystallization from toluene.   
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Scheme 1: 
 
                                                                                      
                                                                                          
                                                                                                                          
                                                                                                                                                                                                
 
n             R1 = R2                 R3 
 
1v  (CH2)2CH3        NO2  
18  (CH2)3CH3        NO2  
19  (CH2)5CH3        NO2 
20  (CH2)2CH3        OMe  
21  (CH2)3CH3        OMe  
22  (CH2)5CH3        OMe  
23  (CH2)2CH3      COOMe  
24  (CH2)3CH3       COOMe 
25          (CH2)5CH3           COOMe 
MMMecccCOOMe COOMe 
COOMe 
39 
40 
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The indoles 16a-c and 27 were then acylated with oxalyl chloride in anhydrous 
ethyl ether at 0°C to give the corresponding indolylglyoxylyl chlorides 17a-c and 
28, which were allowed to react in dry toluene solution and nitrogen atmosphere 
with the appropriate amine, in presence of triethylamine in equimolar quantity to 
neutralize the hydrochloridric acid formed during the reaction of condensation.[24] 
The crude compounds, after washing with a solution of 5% NaHCO3 dil. and then 
with H2O to eliminate the amine not reacted, with HCl dil. 10% and again H2O to 
remove the excess of Et3N, were tritured at 0°C with ethylether to yield the 
indolylglyoxylamides 1v, 18-24, and 29, 30. Their chemical-physical properties 
were determined, and their structures were confirmed by 1H-NMR. (TABLE 2) 
Scheme 2: 
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The synthesis of the target compounds 32 and 33 (R3 = NH2), 35 and 36 (R3 = OH), 
and 38-40 (R3 = COOH) was achieved by the procedures outlined in Schemes 3, 4 
and 5. Briefly starting by indoles, previously prepared 1v, 18-25, we obtain, through 
appropriate reactions, the corresponding compounds featuring a polar group at the 
4’-position of the 2-phenyl ring. 
Scheme 3: 
                                     
           1v, 18, 19                                                                  32, 33, 34 
The Scheme 3 describes the general procedure for the synthesis of the 2-
phenylindolylglyolamide derivatives bearing a NH2 at para position at the 2-phenyl 
ring:[26] N,N-dialkyl-[2-(4-nitrophenyl)indol-3-yl]glyoxylamide derivatives 1v, 18 and 
19 were catalytically hydrogenated over palladium to yield the relative amines 32, 
33 and 34. Their chemical-physical properties and 1H-NMR data are reported in 
TABLE 2. 
Scheme 4: 
                              
H2 / Pd-C 
abs. EtOH 
BBr3 
anh. CH2Cl2 
20-22 35, 36 
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The indolylglyoxylamide derivatives featuring a OH group at R3 (35, 36) were 
obtained through a demethylation of the corresponding methoxy compounds 20 - 
22[34] (Scheme 4) by treatment with BBr3, in anhydrous dichloromethane, in a 
nitrogen atmosphere. At the end of the reaction (TLC analysis), methanol was 
added to the mixture to hydrolyze the excess of BBr3, and crude compounds 35, 36 
were recovered as a solid precipitated after evaporation of the solvent under 
reduced pressure. Their chemical-physical properties and 1H-NMR data are 
reported in TABLE 2. 
Scheme 5 report the synthetic procedure to obtain compounds 37 - 39 by hydrolysis 
of the methyl ester[35] of methyl 4-(3-dialkyl-aminoglyoxylylindol-2-yl)benzoate 
derivatives 23–25 by treatment with lithium hydroxide monohydrate to a 
MeOH/H2O (3:1) solution. The chemical-physical properties and 
1H-NMR data of 
derivatives 23–25 are reported in TABLE 2. 
Scheme 5: 
                                     
            23 –25                                                                         37 – 39 
                                                    
 
LiOH · H2O 
 Me / H2O 
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 MATERIALS AND METHODS: 
Melting points were determined using a Reichert Köfler hot-stage apparatus and are 
uncorrected. Routine nuclear magnetic resonance spectra were recorded in DMSO-
d6 solution on a Varian Gemini 200 spectrometer operating at 200 MHz. 
Evaporation was performed in vacuo (rotary evaporator). Analytical TLC was 
carried out on Merck 0.2 mm precoated silica gel aluminum sheets (60 F-254). 
Silica gel 60 Merck (230-400 mesh ASTM) was used for column chroma-tography. 
Anhydrous reactions were performed in flame-dried glassware under N2. All 
compounds showed ≥ 95% purity. All reagents used were obtained from 
commercial sources. All solvents were of an analytical grade. 
 CHEMISTRY: 
General procedure for the synthesis of:  
2-phenyl-1H-indole derivatives (16a, 16b), methyl 4-(1H-indol-2-yl)benzoate 
derivative (16c), 2-(3-thienyl)-1H-indole derivative (27): 
1 g of polyphosphoric acid (PPA) was added to a mixture of phenylhydrazine 
chlorhydrate (5.0 mmol) and methyl 4-acetylbenzoate (5.0 mmol), or the 
appropriate acetophenone (5.0 mmol), or acetylthiophene (5.0 mmol). The reaction 
was maintained at 75°C for 30 min for 16a (TLC analysis: petroleum ether/ethyl 
acetate, 7:3), at 120°C for 4 h for 16b (TLC analysis: toluene/acetonitrile, 9:1) and 
27 (TLC analysis: chloroform), and at 60°C for 4 h for compound 16c (TLC 
analysis: chloroform). When the starting material was disappeared, the reaction 
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mixture was poured into ice and the precipitated solid was collected by filtration. 
All products were purified by recrystallization from toluene.  
Yield, melting point, and spectral data of compound 16a were reported in 
literature.[16]  
2-(4-methoxyphenyl)-1H-indole (16b). Yield: 84%; m. p.: 231-234 °C; 1H-NMR 
(DMSO-d6, ppm): 3.80 (s, 3H, OCH3); 6.76 (d, 1H, J = 1.8 Hz, ArH); 6.96-7.09 (m, 
4H, ArH); 7.36 (d, 1H, J = 8 Hz, ArH); 7.49 (d, 1H, J = 7.2 Hz, ArH); 7.77-7.81 
(m, 2H, ArH); 11.40 (s, 1H, NH exch. with D2O).  
Methyl 4-(1H-indol-2-yl)benzoate (16c). Yield: 78%; m. p.: 204-207 °C; 1H-NMR 
(DMSO-d6, ppm): 3.87 (s, 3H, COOCH3); 7.02-7.15 (m, 3H, ArH); 7.43 (d, 1H, J=8 
Hz, ArH); 7.57 (d, 1H, J=8 Hz, ArH); 8.02 (s, 4H, ArH); 11.73 (s, 1H, NH exch. 
with D2O). 
 2-(3-thienyl)-1H-indole (27). Yield: 89%; m. p.: 243-245 °C; 1H-NMR (DMSO-d6, 
ppm): 6.76 (d, 1H, J = 0.8 Hz, ArH); 6.94-7.12 (m, 2H, ArH); 7.37 (d, 1H, J = 8 
Hz, ArH); 7.51 (d, 1H, J = 8 Hz, ArH); 7.59-7.67 (m, 2H, ArH); 7.87 (t, 1H, J = 1.5 
Hz, ArH). 
General procedure for the synthesis of:  
(2-phenylindol-3-yl)glyoxylyl chloride derivatives (17a, 17b), methyl 4-(3-
chloroglyoxylylindol-2-yl)benzoate derivative (17c), [2-(3-thienyl)indol-3-
yl]glyoxylyl chloride derivative (28): 
Oxalyl chloride (8.0 mmol) was added dropwise at 0°C to a well-stirred mixture of 
the appropriate indole 16a-c or 27 (4.0 mmol) in freshly distilled diethyl ether (10 
mL). The mixture was maintained at room temperature for 2-24 h (TLC analysis: 
chloroform). A solid precipitate was obtained in the case of compounds 17b and 
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17c, which was collected by vacuum filtration, and immediately used in the 
subsequent reaction. Instead, starting by compounds 16a and 27, it was not 
observed any formation of precipitate: thus, the solvent of reaction was evaporated 
under reduced pressure, and the generated solid was washed with portions of 
anhydrous diethyl ether to give the correspondent acyl chlorides 17a and 28. 
[2-(4-nitrophenyl)indol-3-yl]glyoxylyl chloride (17a). Yield: 60%  
[2-(4-methoxyphenyl)indol-3-yl]glyoxylyl chloride (17b). Yield: 72%  
Methyl 4-(3-chloroglyoxylylindol-2-yl)benzoate (17c). Yield: 80%  
[2-(3-thienyl)indol-3-yl]glyoxylyl chloride (28). Yield: 65% 
General procedure for the synthesis of:  
N,N-dialkyl-(2-phenylindol-3-yl)glyoxylamide derivatives (1v, 18-22), methyl 4-(3-
dialkylaminoglyoxylylindole-2-yl)benzoate derivatives (23-25), N,N-dialkyl-[2-(3-
thienyl)indol-3-yl]glyoxylamide derivatives (29, 30, 31): 
A solution of an appropriate ammine (2.0 mmol) in 5 mL of dry toluene was added 
dropwise to a stirred suspension, cooled at 0°C, of the (2-phenylindol-3-yl)glyoxylyl 
chloride derivatives 17a, 17b (2.0 mmol), or methyl 4-(3-chloroglyoxylylindol-2-
yl)benzoate derivative 17c (2.0 mmol), or [2-(3-thienyl)indol-3-yl]glyoxylyl chloride 
derivative 28 (2.0 mmol) in 50 mL of the same solvent, followed by the addition of 
a solution of triethylamine (2.0 mmol). The reaction mixture was left under stirring 
for 2-24 h at room temperature (TLC analysis with appropriate eluent), and then 
filtered. The collected precipitate was triturated with a NaHCO3 5% aqueous 
solution, washed with water, and collected again to give a first portion of crude 
product. The toluene solution was instead removed under reduced pressure, and the 
oily residue obtained was extracted with CHCl3 and purified by washing with 1) a 
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solution of NaHCO3 dil. 5%; 2) H2O; 3) HCl dil. 10%; and finally 4) H2O. After 
drying with MgSO4, the chloroform solution was evaporated to dryness, and the 
residue was tritured at 0 °C with ethylic ether to yield the crude product, that was 
collected by filtration. In the case of less soluble products, the crude compound 
precipitates together with the triethylamine hydrochloride and was collected, after 
washing with a solution of NaHCO3 dil. 5%, and dried over P2O5 in vacuo.  
All products generally did not require additional purification steps, but in the case 
of dirty compounds they were purified by recrystallization from toluene; only the 
compound 1v, N,N-di-n-propyl-[2-(4-nitrophenyl)indol-3-yl]glyoxylamide, was 
purified by flash chromatography (CHCl3 as eluent), as reported in literature
.[16] 
Yields, melting points, and spectral data are listed in TABLE 2.  
Yield, melting point, and spectral data of compound N,N-di-n-propyl-[2-(4-
nitrophenyl)indol-3-yl]glyoxylamide were reported in literature.[16, 24]  
N,N-di-n-butyl-[2-(4-nitrophenyl)indol-3-yl]glyoxylamide (18). 
Yield: 57%; m. p.: 201-203 °C; 1H-NMR (DMSO-d6, ppm): 0.70-0.78 (m, 6H, 
CH2CH2CH2CH3); 0.97-1.20 (m, 4H, CH2CH2CH2CH3); 1.32-1.53 (m, 4H, 
CH2CH2CH2CH3); 3.07 (2t, 4H, J=8 Hz, CH2CH2CH2CH3); 7.22-7.37 (m, 2H, 
ArH); 7.54 (d, 1H, J=7 Hz, ArH); 7.89 (d, 2H, J=8 Hz, ArH); 8.05 (d, 1H, J=7 Hz, 
ArH); 8.38 (d, 2H, J=8 Hz, ArH); 12.74 (s, 1H, NH exch. with D2O). 
N,N-di-n-hexyl-[2-(4-nitrophenyl)indol-3-yl]glyoxylamide (19). 
Yield: 60%; m. p.: 219-221 °C; 1H-NMR (DMSO-d6, ppm): 0.70-0.82 (m, 3H, 
2CH3); 1.06-1.40 (m, 16H, 8CH2); 2.99-3.07 (m, 4H, 2CH2); 7.28-7.31 (m, 2H, 
ArH); 7.50-7.53 (m, 1H, ArH); 7.84-7.89 (m, 2H, ArH); 8.01-8.03 (m, 1H, ArH); 
8.31-8.37 (m, 2H, ArH); 12.72 ( bs, exch with D2O, 1H, NH). 
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General procedure for the synthesis of:  
N,N-dialkyl-[2-(4’-aminophenyl)indol-3-yl]glyoxylamide derivatives (32-34): 
Pd/C 10% (0.05 g) was added to a suspension of the appropriate N,N-dialkyl-[2-(4‘-
aminophenyl)indol-3-yl]glyoxylamide derivatives 1v or 18 (0.65 mmol) in 150 mL 
of absolute ethanol. The mixture was hydrogenated under stirring for 5 h at room 
temperature and reduced pressure (TLC analysis with appropriate eluent). Once 
hydrogen absorption ceased, the catalyst was filtered off and the ethanolic solution 
was evaporated to dryness at reduced pressure. All products were purified by 
recrystallization from toluene. Yields, melting points, and spectral data of 
compounds 32-34 are listed in TABLE 2. 
General procedure for the synthesis of:  
N,N-dialkyl-[2-(4’-hydroxyphenyl)indol-3-yl]glyoxylamide derivatives (35-36)  
To a stirred suspension of N,N-dialkyl-[2-(4-methoxyphenyl)indol-3-
yl]glyoxylamide derivatives 19 or 20 (0.5 mmol) in 10 mL of dry dichloromethane 
cooled at -10 °C were added dropwise 0.2 mL of BBr3. The mixture was left under 
stir-ring for 30 min. at -10 °C, and subsequently at room temperature for 1h under 
nitrogen atmosphere (TLC analysis with appropriate eluent). Finally, the solution 
was cooled again, and was added 5 ml of methanol to hydrolyze the excess of BBr3. 
The solvent was evaporated at reduced pressure, and the solid precipi-tate was 
washed several times with methanol. The residues obtained were purified by 
recrystallization from toluene (35) or by flash chromatography for compounds 36 
(eluent system, petroleum ether/ethyl acetate in 5:5 ratios).  
Yields, melting points, and spectral data of compounds 35-36 are listed in TABLE 
2. 
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General procedure for the synthesis of:  
4-(3-dialkylaminoglyoxylylindol-2-yl)benzoic acid derivatives (37-39): 
Lithium hydroxide monohydrate (0.3 mmol) was added to a suspension of methyl 
4-(3-dialkylaminoglyoxylylindol-2-yl)benzoate derivatives 22-24 (0.5 mmol) in 20 
mL of a MeOH/H2O (3:1) solution. The mixture was stirred under reflux at 80 °C 
overnight (TLC analysis with appropriate eluent). Subsequently, the solid 
precipitate was eliminate through vacuum filtration, and the solution was acidified 
with HCl dil. 10% to pH 5. The acid precipitated in the solution was collected by 
filtration and generally did not needed any further purification.  
Yields, melting points, and spectral data of compounds 37-39 are listed in TABLE 
2. 
 
BIOCHEMICAL SECTION: 
The binding assay is a biochemical method by which to identify the binding sites 
through the use of radioisotopes. It should make a distinction between the receptor 
and binding site: a receptor site is a competition site for the agonist and antagonist. 
The stimulus produced by the binding of the agonist to the receptor leads to a 
physiological response. On the contrary, a binding site is only an acceptor site to 
which it is not necessarily connected the transmission of a signal and then a cellular 
response. From an experimental point of view, the binding site is related to the 
receptor site when there is a correlation between the affinity of the ligand in vitro 
and in vivo pharmacological potency, tissue specificity, stereospecificity, 
saturability, reversibility and high affinity. The method of the radioactive binding 
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provides the incubation of a biological preparation, which contains the receptor 
with a radiolabelled ligand specific for that receptor, under conditions of time, 
temperature and pH sufficient to attain equilibrium. During the incubation time, a 
certain amount of ligand (L) with the receptor (R) forms the receptor-ligand 
complex (RL); the excess amount of  free L, is separated from the RL by 
subsequent vacuum filtration. This procedure must be made quickly and with cold 
buffer so as to minimize the possibility of dissociation of the complex. The 
formation of the complex RL is a reversible reaction regulated by the law of mass 
action and characterized by constants of association (K1) and dissociation (K2): 
L  +  R                          RL  
At the equilibrium, the rate of association and dissociation assume the same value, 
then:   
ᶹa = ᶹd                 K1  x  [RL]                     [RL]    =      K1 
                                                                           [L][R]           K2 
K1 / K2  = Ka association constant. 
The total binding of the radioligand to the receptor (LT) is determined incubating 
the membranes with the radioligand, and is composed of specific binding (SB) and 
non-specific binding (NB) of the radioligand. The NB corresponds to the amount of 
radioligand which binds to non-specific structures not receptorial and is determined 
incubating the membranes with the radioligand, in the presence of saturating 
concentration of a ligand specific and selective for the same receptor site. In this 
way, competing with the radioligand, but being in a concentration greater, occupies 
           K1 
   
      K2 
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all the binding sites. The non-specific binding must be as low as possible (20-30% of 
total). Then the specific binding is calculated as the difference between total binding 
(measured in the absence of competitive agent ) and represents 70-80% of total 
binding. Membranes containing the receptor of interest are incubated with a 
constant concentration of radioligand in the presence of increasing concentrations 
of competitor ligand. Incubating the membranes with the radioligand is possible to 
quantify the power of the ligand of interest. In terms of competitor the 
concentration of that effectively inhibits by 50% the specific binding of the 
radioligand (IC50). The IC50  can be calculated through the analysis of non-linear 
regression. Using an appropriate table, the percentages of inhibition of radioligand  
binding of the are converted into probability of inhibition. The values obtained are 
indicated in the ordinate, while on the abscissa are reported the corresponding 
concentrations in logarithmic scale of the competitor.( FIGURE(12))From the equation 
of the straight line is possible to obtain the value of IC50.  
 
 
 
The IC50 determined in binding studies is transformed into inhibition constant Ki of 
the competitor, through the use of the equation of Cheng and Prusoff: 
FIGURE(12): Graph of the specific binding (circles curve), the nonspecific binding (empty squares straight line) and total 
(squares curve blacks). 
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Ki  =  IC50  / ( 1 + [L] / Kd ) 
Where: Ki   =  inhibition constant of the competitor 
              Kd  = dissociation constant of the radioligand 
             [L] =  concentration of the radioligand 
 
FIGURE(13): example of curve placement. 
Specific binding, as a saturable phenomenon, increases until reaching a plateau 
(steady state). The nonspecific binding increases linearly as a function of ligand 
concentration. This is due to the fact that the non-specific binding is given by the 
interaction of the ligand with the receptor sites, or more simply by radioactivity 
absorbed by the filter. The measurement of residual radioactivity is performed by a 
scintillator in the liquid phase that provides the disintegrations per minute (dpm). 
From the value of dpm is possible to trace the μCi present in the samples through the 
following relation: 
1 μCi  =  2.220.000 dpm 
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Finally, knowing the specific activity of the radioligand (SA = µCi / mol), is 
possible to determine the nanomoles of radioligand present as a complex LR to 
equilibrium (Bound = pmol (or fmol) / mg of protein). In this work, the studies 
about the affinity of TSPO ligands were performed using preparations of rat kidney 
membrane,as,and radioligand [3H]PK11195. 
 MATERIALS AND METHODS: 
The preparation of the mitochondrial membranes of rat kidney was carried out as 
described by Campiani et al.( 1996 ) and Trapani et al.( 1997 ). The kidney was 
minced and suspended 1:10 in buffer 50 mM Tris-HCl, pH 7.4 (T50), 0:32 M 
sucrose containing, 1 mM EDTA and protease inhibitors ( benzamidine 160 
mg/ml, bacitracin 200 mg/ml, trypsin inhibitors 20 mg/ml). The obtained 
suspension was homogenized and then centrifuged at 600 x g for 10 minutes at a 
temperature of 4° C. The supernatant (S1) was again centrifuged at 10000 x g for 10 
minutes at 4 ° C. The precipitate obtained from the latter centrifugation (P2) was 
resuspended in relation 1:20 with buffer T50 and recentrifuged at 10000 x g for 10 
minutes at 4° C. By centrifugation was obtained a pellet (P3) containing the 
mitochondrial membranes that were stored at -20 ° C until the moment of their use. 
 DETERMINATION OF PROTEIN 
CONCENTRATION: 
To determine the protein content, present in a biological sample, was performed a 
proteic dosage that includes the use of radioactive commercial Biorad Protein 
Assay (Bradford method colorimeter). This assay employs the dye Coomassie 
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Brilliant Blue G-250, which changes color in response to bond with the amino acid 
residues of which mainly aromatic or basic. The assay was performed by adding 
aliquots of the membranes to 200 μl of reagent and the quantity of distilled water 
necessary to reach a coloring bluish, whose intensity is directly proportional to the 
concentration of proteins. TABLE 3 
 Buffer Membranes Water MQ Biorad 
B 20 μl / 780 µl 200 µl 
B’ 20 µl / 780 µl 200 µl 
M / 20 µl 780 µl 200 µl 
M’ / 20 µl 780 µl 200 µl 
TABLE 3: Preparation protein assay 
It was then measured the absorbance in a spectrophotometer at a wavelength of 595 
nm. From the absorbance value obtained was the concentration of protein present 
in the sample by reference to the calibration curve obtained using solutions of γ-
globulin to increasing conncentrations (2.5 - 20 μg/mL). (Figura (14)) 
 
FIGURE(14): Calibration curves Biorad Red 
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 DETERMINATION OF THE BINDING OF 
RADIOLIGAND TO THE TSPO IN PRESENCE 
OF NEW SYNTHESIZED COMPOUNDS: 
The method involves the incubation of aliquots of membranes containing 
approximately 15 μg of protein, with a constant concentration of radioligand ([3H] 
PK 11195), 0.6 nM for 90 minutes at 4 ° C. The nonspecific binding is determined 
incubating an aliquot of membranes in the presence of PK11195 1 μM (not labeled), 
as an agent competitor. The new synthesis compounds were added to the 
incubation mixture at increasing concentrations (0.1 nM-10μM) after being 
dissolved in dimethyl sulfoxide (DMSO). After 90 minutes of incubation the 
samples were subjected to vacuum filtration on filters of glass wool Whatmann 
GF/C and performing two washes in a tube with 4 ml of cold 50 mM Tris buffer. 
Each filter is then inserted into a plastic vial with 4 ml of Ultima Gold TM scintillation 
liquid. The counts of the residual radioactivity on the filter is effected by a 
scintillator in the liquid phase (TRI-CARB 2800 TR). From the curve of competing 
ligand, which competes for binding to the receptor site, it is possible to determine 
the concentration of competitor which inhibits 50% of the specific binding of the 
radioligand (IC50) and through the equation of Cheng-Prusoff (1973) is calculated 
the inhibition constant Ki. (an example of binding curve is reported in FIGURE(15). 
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FIGURE(15): Graph example of binding of the compound 34. 
In this work binding studies were performed to assess the activity of newly 
synthesized compounds for Translocator protein 18kDa. Has been verified that the 
structural changes designed on the pharmacophore model proposed by Dalpiaz 
(Dalpiaz  et al.,1995) have really led to a lowering of the constant Ki. The Ki values 
were reported in TABLE 4. 
 
PROLIFERATION STUDIES:                     
On the basis of  their structures and affinity costant values to TSPO,  the compounds 
21, 22, 30 and 31 were selected to perform proliferation studies in metabolic stress 
conditions like the ones exerted in nutrient deprivation (starvation). The condition 
of  serum deprivation for proliferation assay is common used render the cells 
qluiescents and ti have more reliable results after cell stimulation. By the way, some 
cells are more susceptible towards low serum medium in that they go into 
spontaneus apoptosis. A human cell line derived from a glial lineage (U87MG) was 
used for these preliminar experiments. This cell line was provided by the National 
Institute for Research of  Cancer (ICLC) in Genoa. These compounds were selected 
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on the basis of  their affinity, evaluated in terms of  Ki. They have substituents “Ar” 
with a good ratio hydrophilicity / lipophilicity, essential for interactions with 
binding site, and also have the right dimensions that allow them to fit perfectly in 
the pocket receptor. The compounds 21 and 22 carry, in position 2 of  the indole, a 
p-OCH3-C6H4. The compounds 30 and 31, however, carry the thiophene. What 
distinguishes between them the two pairs of  compounds are the substituents R1 and 
R2, which may be chains butyl or hexyl. This choice has been made to verify that 
the possible neuroprotective effect is due to the substituent in position 2 of  the 
indole or to the length of  the alkyl chains on the amide nitrogen, to increase of  
which has larger dimensions but also greater capacity for torsion of  molecule. 
 Thawing procedure 
The cells, stored in liquid nitrogen in criovials, have been quickly heated in the bath 
at 37° C and harvested. Following, pre-heated complete medium is added very 
slowly ,and the whole is then centrifuged at 100 xg for 5 minutes. The pellet 
obtained is then resuspended in an appropriate volume of heated complete medium. 
The suspension obtained is then transferred into a flask of 75 cm2, already 
containing complete medium, so as to obtain total 10 ml and it was then 
maintained at 37° C in the incubator with a humidified atmosphere of 5% CO2 and 
95% of O2. 
 Conditions of cell culture: 
The cells were plated and maintained in the appropriate sterile complete culture 
medium consisting of: 
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 RPMI-1640 (1:1); 
 10% of fetal bovine serum (FBS); 
 Pen-Strep 100 U/mL (antibiotic which prevents the proliferation of 
bacteria.) 
 L-glutamine 2 mM; 
 1% non-essential amino acids; 
   
FIGURE(16): U87MG cells. Low density (on the left) and high density (on the right). 
 
 Splitting technique: 
This technique, also called trypsinization, allows the detachment of eukaryotic cells 
adherent to a solid substrate. The trypsinization is done through the use of a 
solution containing the enzyme trypsin (a protease that breaks down the proteins in 
the joints, creating interconnections between cells), and EDTA which at high 
concentrations chelates Ca2+, essential for cell adhesion. The experimental 
procedure involves the use of the culture medium, the solution of Trypsin-EDTA 
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and saline solution, all previously heated to 37° C. The culture medium is aspirated 
from the flask using a glass Pasteur connected to a vacuum pump, then a washing is 
carried with the saline and aspirating means. Subsequently add a volume (related to 
the number of cells present in the flask) of the solution Trypsin-EDTA and left in 
incubation at 37 ° C for a few minutes. If, observing with an optical microscope, the 
cells contained in the flask are detached, there are introduced 3-4 ml of culture 
medium that neutralizes the trypsin. Then is withdrawn the suspension by washing 
well the surfaces of the flask with the medium and the whole is transferred in a 15 
ml falcon previously prepared with 2 ml of culture medium. The cell suspension is 
then centrifuged to 300 rpm for 5 minutes at r.t. The supernatant is aspirated 
carefully and the pellet obtained is resuspended in a suitable volume of culture 
medium by homogenization accurate. 
 Cell seeding: 
In a 96-multiwell were seeded at a density ~8000 cells / well. Cells were maintained 
at 37° C in the incubator with a humidified atmosphere of 5% CO2  for 24h.The day 
after, cells were added with   compounds in serum deprivation using  1% FBS. 
PK11195 was used as positive controls. Indeed it was been reported thet PK11195 
increased the growth rate of C6 glioma cells by 20-30% in the nanomolar range in 
serum free medium. [37] The control cells were treated with veihcle alone the 
compounds. The cells were treated in duplicate with the compounds 21, 22, 30 and 
31 at three different concentrations (10 nM, 100nM and 1 µM). After 48 h the MTS 
assay and crystal violet staining were performed . 
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 MTS assay: 
MTS is a colorimetric method that allows to determine the number of viable cells in 
a proliferation or cytotoxicity assay. It is based on use of the reagent liquid 
tetrazolium (MTS) that within the cells is reduced to formazan (composed of 
bluish) by mitochondrial enzyme succinate dehydrogenase. Cell viability was 
determined spectrophotometrically by measuring the conversion of the MTS 
substrate to the formazon product which is directly proportional to the number of 
viable cells. The reaction can take place only in metabolically active cells and the 
value of optical density, obtained by spectrophotometric reading, can be correlated 
to the quantity of viable cells present.  
FIGURE(17):  In a 96-multiwell were seeded ~8000 cells / well. 10 nM PK11195 was used as positive controls. The untreated cells 
were cultured with complete medium and with deprivation of 1% FBS. The cells were treated in duplicate with the compounds 21, 22, 
30 and 31 at three different concentrations (10 nM, 100 nM and 1  M). 
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FIGURE(18): Reaction scheme leading to the formazan. 
 
 Crystal violet:  
Crystal violet (CV) is a triphenylmethane dye  (4-[(4-dimethylaminophenyl)-phenyl-
methyl]-N,N-dimethyl-aniline)  also known as Gentian violet. The most commonly 
used application for this dye is as the primary microbiological stain in the Gram-
staining procedure  used to The  CV assay was initially used to quantify the cell 
number in monolayer cultures as a function of the absorbance of the dye taken up 
by the cells differentiate  bacteria. However, this method  is now being  used, after 
some  modification, for a wide number of applications including determination of 
cytotoxicity or cell death produced by chemicals, drugs, or toxins from pathogens , 
to determine cell viability or  to determine cell proliferation under different testing 
conditions. CV is a simple assay that is useful for obtaining quantitative  
information about the relative density of cells adhering to multi-well cluster  dishes.  
However, note that this dye stains DNA and the color of the dye depends upon the 
pH of the solution. Upon solubilization, the amount of dye  taken-up by the 
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monolayer and the intensity of the color produced are proportional to cell  
number.[36] 
 
FIGURE(19): Crystal violet solution. 
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RESULTS AND DISCUSSION: 
 In this study, a series of novel N,N-dialkyl-2-arylindol-3-ylglyoxylamide TSPO 
ligands was designed, synthesized and tested for their affinity toward TSPO and for 
their ability to influence cell growth in vitro. 
TABLE 4: Ki values for the compounds tested for displacement of 3HPK 11195 in membranes of rat kidney. 
 
 
 
 
n R1=R2 Ar Ki (nM) 
[a] 
Id (CH2)2CH3 Ph 12,2±1,0 
Ie (CH2)3CH3 Ph 7,5±0,7 
If (CH2)4CH3 Ph 16,0±0,2 
Ig (CH2)5CH3 Ph 1,4±0,2 
20 (CH2)2CH3 p-OCH3-C6H4 5,82±0,5 
21 (CH2)3CH3 p-OCH3-C6H4 20,34±2 
22 (CH2)5CH3 p-OCH3-C6H4 4,037±0,4 
23 (CH2)2CH3 
p-COOCH3-
C6H4 
3,101±0,3 
24 (CH2)3CH3 
p-COOCH3-
C6H4 
2,735±0,3 
25 (CH2)5CH3 
p-COOCH3-
C6H4 
3,275±0,3 
29 (CH2)2CH3 thiophene 1,234±0,12 
30 (CH2)3CH3 thiophene 2,829±0,3 
31 (CH2)5CH3 thiophene 0,8903±0,1 
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32 (CH2)2CH3 p-NH2-C6H4 44,4±0,5 
33 (CH2)3CH3 p-NH2-C6H4 132,8±13,3 
34 (CH2)5CH3 p-NH2-C6H4 3,820±0,4 
35 (CH2)2CH3 p-OH-C6H4 16,3±1 
36 (CH2)3CH3 p-OH-C6H4 25,65±2,6 
37 (CH2)2CH3 p-COOH-C6H4 343,0±10 
38 (CH2)3CH3 p-COOH-C6H4 406,4±41 
39 (CH2)5CH3 p-COOH-C6H4 183,9±20 
[a] Ki values are expressed as mean ± SEM of three determinations. 
 At first, the analysis of the binding affinity of all the novel compounds 20-25, 29-39 
for TSPO was performed in order to select the ligands with the highest affinity and 
evaluate their  potential as neuroprotective agents. The binding affinity to TSPO of 
the novel compounds was determined in competition binding studies using the 
radioactive ligand [3H]PK11195 in homogenates of rat kidney membranes. From 
the analysis of the competition curves for each ligand, the value of Ki, i.e. the 
concentration of the compound that inhibits the binding of [3H]PK11195 to the 
mitochondrial membrane of rat kidney  of 50%, is derived. In TABLE 4 the affinity 
data of the newly synthesized products 20-25, 29-39 are reported, together with 
those of derivatives Id, Ie, and Ig for comparison purpose. It should be noted that, 
in general, we have obtained highly affine TSPO ligands, as most of the novel 
compounds show Ki values in the low nanomolar range. The best performant 
modification at 2-position of the indole scaffold results to be the insertion of a 
thienyl nucleus, showing compounds 29, 30 and 31 the highest affinity of the whole 
series with Ki values of 1.234 nM, 2.829 nM, and 0.8903 nM. In addition, the 2-
thienyl derivatives 29, 30 and 31  present a gain in affinity with respect to their 
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corresponding 2-phenyl-substituted counterparts Id, Ie, and Ig, of  about 10-, 3-, 
and 2-fold, respectively. These data could be rationalized by hypothesizing that the 
thiophene ring, due to its lipophilicity and limited steric-demanding dimensions, 
permits an efficacious lipophilic interaction at the level of the L1 pocket.  
The insertion of different substituents at the para position of the 2-phenyl ring 
(derivatives 20-25, 32-39) produces effects on TSPO affinity that depend both on 
the hydrophilic/lipophilic characteristics of the group and the length of the alkyl 
chains bounded to the glyoxylamide nitrogen, sometimes in an interdependent way. 
A number of main structure-affinity relationships could be drawn.  
Compounds bearing an highly hydrophilic 4’-substituents, such as NH2, OH, and 
COOH show a general decrease in affinity with respect to their 4’-unsubstituted 
analogs, with few exceptions: the amino and the hydroxy groups are tolerated in 
the presence of N,N-dihexyl and N,N-dipropyl side chains, respectively (34 Ki 3.820 
nM vs Ig Ki 1.4 nM, and 35 Ki 16.3 nM vs 1d Ki 12.2 nM). 
Conversely, insertion of a 4’-lipohilic group such as OCH3, COOCH3, yields 
compounds 20-25 with comparable or higher TSPO affinity than the unsubstituted 
counterparts, with the only exception of compound 21.  
Taken together all these data seem to indicate that the nature of  the L1 pocket is 
mostly lipophilic, as polar substituents, differently from the lipophilic ones, are not 
able to engage efficacious interactions with it. 
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FIGURE(20):   Effect of novel TSPO ligands on cell growth. U87MG cells.Results are expressed as a percentage of  viable 
cells observed after treatment with ligands vs. untreated control cells (100%) and shown as mean SEM derived from least three 
separate experiments done in duplicate. P < 0:05 with respect to control, one-way ANOVA (Newman–Keuls test). 
 
In light on SAR analysis, the compounds 21, 22, 30 and 31 were selected to perform 
proliferation studies in starvation. Firstly, it has been observed a reduction of  the 
not treated cell number cultured in 1% FBS in respect to complete medium (above 
30%) (data not shown), indicating a reduction in growth rate due to a  cell 
quiescient state or a spontaneous apoptosis. The data obtained with the novel TSPO 
ligands suggest that in each sample of  cells, treated with the nanomolar 
concentrations of  compounds, there was an increase in growth rate in respect to the 
control with DMSO. However, compound 21 has proved only a trend toward 
increase (not statistically significant). For the other compounds, the statistical 
analysis showed a significant concentration-dependent increase the cell growth. 
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Particularly effective is compound 30 which, at increasing concentration, showed 
increasing neuroprotective activities (FIGURE(20)). The classical TSPO ligand  
PK11195 elicited a 30% increase in cell number at 10 nM, according to preavious 
literature.[37] These findings suggest that TSPO may be involved in the control of  cell 
growth: a possible mecchanism eliciting such effect is the production of  steroids. 
Indeed, it is well-known that TSPO-ligands interaction led to increase  in 
production of  steroids, that in turn exert benefical and survival effects on cell 
metabolism. If  such preliminary results are confirmed even in a cellular model of  
primary neurons or in a neurodegenerative cell model, these compounds may be 
used as versatile scaffold for the design of  novel neuroprotective agents. 
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